布地奈德、复方异丙托溴铵雾化吸入治疗肺炎支原体感染后慢性咳嗽的临床效果评价

目的探讨肺炎支原体感染后慢性咳嗽应用布地奈德、复方异丙托溴铵雾化吸入治疗的临床效果。方法将我院2016年5月～2018年2月期间收治的108例肺炎支原体感染后慢性咳嗽患儿作为此次研究病例,按照计算机表法将其分为研究组与对照组,各54例,对照组应用氨溴索注射液雾化吸入治疗,研究组应用布地奈德与复方异丙托溴铵雾化吸入治疗,比较治疗效果。结果研究组治疗总有效率为96.29%,对照组治疗总有效率为79.63%,治疗第1天,两组患儿临床症状咳嗽评分无明显差异,治疗第3、5、7天临床咳嗽症状评分显著低于对照组,研究组吸药依从率为87.04%,与对照组(57.41%)比较差异有统计学意义(P0.05)。结论布地奈德、复方异丙托溴铵雾化吸入治疗肺炎支原体感染后慢性咳嗽患儿的临床疗效确切,值得应用。

Clinical evaluation of budesonide and compound ipratropium bromide inhalation for chronic cough after infection with Mycoplasma pneumoniae

Objective To investigate the clinical effect of budesonide and compound ipratropium bromide inhalation therapy for chronic cough after infection with Mycoplasma pneumoniae.Methods 108 children with chronic cough after infection with Mycoplasma pneumoniae from May 2016 to February 2018 were enrolled in this study.They were divided into study group and control group according to computer table method,with 54 cases in each group.The control group was treated with ambroxol injection by nebulization,and the study group was treated with budesonide and compound ipratropium bromide.The treatment effects were compared.Results The total effective rate of the treatment group was 96.29%,and the total effective rate of the control group was 79.63%.On the first day of treatment,there was no significant difference in the clinical symptom cough score between the two groups.The clinical cough symptom scores on the 3rd,5th and 7th day of treatment were significantly lower than those of the control group.There was significant difference in the drug-subject adherence rate between the study group(87.04%)and the control group(57.41%),which was statistically significant(P<0.05).Conclusion The clinical efficacy of budesonide and compound ipratropium bromide in the treatment of children with chronic cough after Mycoplasma pneumoniae infection is accurate and worthy of application.